Marion Corouge

Marion Corouge appears in the volume as a medical researcher whose principal contribution is the systematic account of hepatitis C infection in the chapter “Hepatitis C: Epidemiology, Diagnosis, Natural History and Therapy.” Listed with Stanislas Pol, Anaïs Vallet-Pichard, and Vincent O. Mallet, she is affiliated with Université Paris Descartes, APHP, Hôpital Cochin, the hepatology unit, INSERM U-1016, and Institut Cochin in Paris. Her presence is therefore tied less to a personal narrative than to the production and organization of contemporary hepatology knowledge.

Identity and Scholarly Setting

Marion Corouge is presented through a Paris research and clinical network that joins university medicine, hospital hepatology, and biomedical investigation. The chapter’s authorship places her within a team addressing hepatitis C as both a liver infection and a systemic disease. That framing is important: the volume emphasizes that HCV can produce autoimmune, dermatological, and renal disease, while also creating major problems for patients with chronic kidney disease, dialysis, and transplantation.

Her chapter belongs to a larger nephrology and transplantation project prompted by the recognition that HCV affects more than the liver. The volume’s editorial rationale connects this field to the KDIGO clinical practice guidelines on the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Corouge’s credited role consequently participates in a broader international effort to stabilize terminology, diagnostic thresholds, treatment indications, and risk assessment across specialties.

Epidemiology and Diagnosis

The chapter associated with Marion Corouge describes HCV as a worldwide public-health burden, with an estimated prevalence of 3 percent and approximately 170 million infected people. Although new infections were declining in industrialized countries, morbidity, mortality, and the economic costs associated with chronic infection were expected to rise. Models projected continuing increases in hepatocellular carcinoma and HCV-related mortality until about 2015, particularly as fibrosis progressed toward cirrhosis or liver cancer in patients with additional risks such as metabolic syndrome or heavy alcohol intake.

The diagnostic framework distinguishes exposure from active disease. HCV infection is initially identified through anti-HCV antibodies detected by third-generation ELISA assays, but antibodies alone cannot establish whether infection has resolved or remains chronic. Active infection requires detection of HCV RNA in serum by sensitive molecular testing, with an assay threshold of approximately 15 IU/ml; chronic infection is defined by the combined presence of anti-HCV and HCV RNA. This separation between serological status and viral replication gives the chapter a precise clinical logic and prevents an antibody-positive result from being treated as a complete description of a patient’s current disease.

The chapter also situates diagnosis within viral diversity. Six HCV genotypes and numerous subtypes are described, with genotype 1 the most prevalent worldwide. Genotype 1b is especially prevalent in Japan and Europe, genotype 1a in the United States, genotype 2 in clusters around the Mediterranean, genotype 3a in the Indian subcontinent and among European intravenous drug users, genotype 4 historically in Egypt and Africa, and genotype 6 mainly in south China. These geographic and genetic patterns matter because genotype helps determine treatment strategy and expected response.

Natural History and Extrahepatic Disease

Corouge’s contribution presents HCV as an infection whose course can remain hidden while progressively shaping multiple organs. In Europe, acute HCV accounts for about 10 percent of acute hepatitis cases, yet 50 to 90 percent of acute infections may be asymptomatic. Spontaneous resolution occurs in roughly 30 percent of cases and varies with the route of transmission, symptomatic presentation, age at infection, and immune status. Polymorphisms in IL28B, including the CC, TT, and CT genotypes, were associated with different rates of spontaneous clearance, with the CC genotype linked to a clearly higher clearance rate.

Once infection becomes chronic, assessment must include both hepatic and extrahepatic effects. The chapter specifically identifies cryoglobulinemia-associated vasculitis as an extrahepatic consequence and recommends evaluating liver stage and grade through liver biopsy or noninvasive methods. Biochemical indices such as Fibrotest, Fibrometre, Hepascore, Forns index, and Fib-4, together with elastometry by FibroScan, can avoid approximately half of liver biopsies and permit yearly follow-up of fibrosis in untreated patients.

The renal dimension is particularly important in the volume’s overall argument. HCV is described as the major cause of mixed cryoglobulinemia, a systemic vasculitis that may involve arthralgias, arthritis, Raynaud phenomena, purpura, peripheral neuropathy, hypocomplementemia, and kidney disease. Renal manifestations include nephrotic or non-nephrotic proteinuria, hematuria, and varying reductions in estimated glomerular filtration rate. Acute nephritic syndrome occurs as a presentation in about 25 percent of affected patients, while nephrotic syndrome occurs in about 20 percent. Purpura, arthralgias, or neuropathy may precede kidney disease by several years. HCV is mainly associated with type II mixed cryoglobulinemia, and type I membranoproliferative glomerulonephritis, also called cryoglobulinemic glomerulonephritis, is identified as the most frequent renal lesion.

Therapy and Clinical Development

The therapeutic account connected with Marion Corouge describes treatment as appropriate at any stage of HCV infection, with timing and duration guided by viral kinetics and genotype. In acute infection, persistent HCV RNA after an average of 12 weeks indicates a 24-week course of pegylated interferon; treatment is extended to 48 weeks when HCV RNA remains detectable at week 4 or week 12. In chronic infection, antiviral therapy may be considered for any patient under the EASL clinical practice guidelines, with particular emphasis on chronic fatigue, chronic hepatitis accompanied by necroinflammation or fibrosis above Metavir stage 1, and symptomatic extrahepatic disease such as cryoglobulinemia-associated vasculitis with renal involvement.

The standard treatment described for the period was pegylated interferon combined with ribavirin, while genotype 1 infection increasingly received direct-acting antiviral triple therapy with telaprevir or boceprevir alongside pegylated interferon and ribavirin. Combination therapy achieved sustained virologic response in more than half of patients with chronic infection. The chapter treats sustained virologic response as a complete recovery of infection, involving virologic recovery and, in the absence of liver comorbidities, remodeling of fibrosis.

The arrival of direct-acting antiviral drugs marks the chapter’s decisive forward movement. A better understanding of the viral cycle and its enzymes produced agents directed against NS3/NS4A protease, NS5B polymerase, and broader-spectrum targets such as NS5A or viral entry, alongside nonspecific approaches including new interferons and cyclophilin inhibitors. In genotype 1 patients, first-generation protease inhibitors increased sustained virologic response rates by approximately 20 to 30 percent. Telaprevir-based triple therapy produced sustained virologic response in about 75 percent of previously untreated genotype 1 patients, with a total treatment duration of 24 weeks possible for roughly two thirds of patients who achieved extended rapid virologic response. Boceprevir-based treatment produced sustained virologic response in about 65 percent of comparable patients after a four-week lead-in with standard therapy and a total triple-therapy course of 24 to 44 weeks.

Treatment history also altered the meaning of response. Among previously treated genotype 1 patients, triple therapy achieved sustained virologic response in approximately 85 percent of previous relapsers, 55 percent of previous partial responders, and 30 percent of previous null responders. The drugs were approved in 2011 after temporary compassionate-use authorization in some countries for cirrhotic genotype 1 patients who had previously relapsed or responded only partially to combination therapy. Their limitations remained substantial: cutaneous rash, anemia, cost, compliance, viral resistance, and drug interactions requiring deliberate education of both patients and physicians.

Renal Disease, Dialysis, and Transplantation

The subject’s credited chapter is part of a book that follows HCV into chronic kidney disease, hemodialysis, and kidney transplantation. In hemodialysis populations, the epidemiology changed sharply after the identification of HCV as the major cause of non-A, non-B hepatitis in 1989. During the 1990s, dialysis patients were recognized as a high-risk group because of transfusions and probable nosocomial transmission within dialysis units. As blood-screening sensitivity improved and erythropoiesis-stimulating agents reduced transfusion requirements, the estimated risk of post-transfusion hepatitis C in the United States fell from about 0.5 percent per blood unit in the 1980s to approximately 0.0001 percent, or one case per million blood units.

The consequences of HCV in dialysis extend beyond infection counts. A meta-analysis of seven observational studies involving 11,589 patients found an independent association between anti-HCV positivity and mortality, with a relative risk of 1.34. Liver cirrhosis and hepatocellular carcinoma were more frequent causes of death among anti-HCV-positive dialysis patients, and the unadjusted relative risk of liver-related mortality was 5.89 compared with anti-HCV-negative patients. A large Australia and New Zealand study of 23,046 patients likewise found higher all-cause mortality over ten years, with a hazard ratio of 1.25 and an adjusted hazard ratio of 5.79 for hepatic failure, although hepatic failure remained infrequent.

The transplant evidence introduces an important contrast: HCV increases risk relative to uninfected recipients, but transplantation still generally offers better survival than remaining on dialysis. A meta-analysis of eight clinical trials involving 6,365 patients found a relative risk of mortality of 1.79 associated with HCV infection, partly because of increased liver-related death. Yet several comparative studies showed lower mortality for HCV-infected patients who received kidney transplants than for those who remained on the waiting list. In one analysis, the relative risk of death after transplantation was 0.31 during the seven- to forty-eight-month post-transplant period. These findings support transplantation as the preferred renal replacement therapy for an HCV-infected patient with end-stage renal disease, provided that pretransplant liver biopsy does not show advanced liver injury.

HCV also complicates graft survival. One comparison of 488 anti-HCV-positive recipients with 2,877 seronegative recipients found an adjusted relative risk for graft loss of 1.53. Registry data from Australia and New Zealand showed worse five-year graft survival in the anti-HCV-positive cohort, with an adjusted hazard ratio of 1.71 for graft failure. Graft loss was more likely to result from glomerulonephritis or chronic allograft nephropathy, although other studies did not demonstrate a statistically significant increase. This tension between improved patient survival through transplantation and increased risks to the graft captures the clinical complexity surrounding the disease that Corouge’s chapter helps define.

Narrative and Scientific Significance

Marion Corouge is not characterized through scenes, dialogue, or a personal arc. She is visible through authorship, affiliation, and the conceptual architecture of a chapter that moves from global prevalence to molecular diagnosis, natural history, extrahepatic disease, antiviral therapy, and the complications of renal replacement. Her role is that of a contributor to a collective scientific voice rather than a solitary protagonist.

That collective voice transforms HCV from a narrowly hepatic diagnosis into a chain of linked clinical states: antibody exposure, detectable RNA, chronic infection, fibrosis, cirrhosis, cryoglobulinemic vasculitis, renal injury, dialysis risk, and transplant decision-making. The progression also records a history of medical knowledge, from serological screening and molecular confirmation to genotype-directed treatment and direct-acting antiviral therapy. Corouge’s significance lies in helping make those distinctions operational: they determine who is considered actively infected, which organs require evaluation, when treatment is justified, how response is measured, and how the risks of dialysis and transplantation are interpreted.